Navigation Links
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO

16 mg/m2. Grade 3 peripheral neuropathy was observed in only 2 patients. -- On the 3-week schedule, 3 patients received a 1-hour infusion (16 mg/m2) and no dose-limiting toxicity was observed. -- On the 3-week schedule, no Grade 3 diarrhea was seen in the 6 patients receiving the 3-hour infusion at 20 mg/m2. A Grade 3 increase in liver function tests was observed in a patient with progressive liver disease.

Dose escalation is continuing on both the 3-week, 3-hour infusion schedule (currently at 25 mg/m2) and on the 4-week, 3-hour infusion schedule (currently at 20 mg/m2).

A second Phase 1 trial is currently exploring a single 3-hour infusion every 3 weeks (36-42 mg/m2). In this trial partial responses have been observed in patients with pancreatic and ovarian cancers and signs of activity in approximately 25% of patients, including a partial response in a heavily-pretreated patient with ovarian cancer (6 prior therapies; 31% tumor shrinkage by RECIST; 53.7% CA125 decline at end of study) and stable disease in patients with pancreatic, ovarian, non-small cell lung cancers and sarcomas.

Roche and Kosan plan to advance KOS-1584/R1645 into Phase 2 trials in the second half of 2007. The final dose and schedules for the Phase 2 trials will be based on clinical activity, dose intensity, side effect profile and schedule compatibility with established chemotherapy regimens.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of ta
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
(Date:12/19/2014)... 2014 (HealthDay News) -- A new study suggests a ... severe hot flashes and night sweats -- and higher ... flashes are common during menopause, affecting about 60 percent ... women after menopause, since they then face a higher ... suggest women who exhibit moderate or severe menopausal symptoms ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. ... were exposed to high levels of air pollution late in ... U.S. study suggests. Researchers found that of nearly 1,800 ... exposed to the most air pollution during pregnancy were twice ... And exposure during the third trimester, specifically, showed the strongest ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Traveling through ... the measles virus to three others within a four-hour ... spread, a new report shows. "The exposures in ... domestic rather than an international terminal, highlighting the fact ... by Jared Vega, an infectious disease specialist at the ...
(Date:12/19/2014)... Steven Reinberg HealthDay ... If you can,t balance on one leg for at least ... Japanese researchers suggest. Difficulty standing on one leg may ... which means the risk for more serious strokes is high, ... Stroke . "Individuals showing instability while standing on one ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Futureā€ and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
... HealthDay Reporter , THURSDAY, Feb. 16 (HealthDay ... struggle with heart failure, experts say new treatments have ... for these patients. "The present environment for heart ... that will truly remove the term ,failure, from the ...
... Hall Institute scientists have revealed new details about ... system, identifying in the process potential new therapeutic ... Jeff Babon and Professor Nick Nicola, from the ... respectively, study interactions between internal cell signalling proteins ...
... fracture easily. It is a major complication of spinal cord ... A new clinical trial conducted by University of Iowa researchers ... bone through programmed electrical stimulation of the muscle significantly slows ... The focus on quantifying the effective dose of load is ...
... -- In an effort to reduce and eventually eliminate cancer ... Cancer Center at Jefferson has established the Center ... Mitchell, M.D., FACP , a medical oncologist at Thomas ... Medical Oncology in the Department of Medical Oncology at Jefferson ...
... Reporter , THURSDAY, Feb. 16 (HealthDay News) -- A sweetener ... of arsenic, new research suggests. Researchers at Dartmouth College ... found in some infant formulas. Their report appears in the ... Arsenic is a natural element that can contaminate groundwater. As ...
... a free, non-promotional online program designed to support ... chronic pain. This study tested painACTION.com,s ability to ... with chronic migraine headaches. A total of 185 ... were more confident that they could prevent headaches ...
Cached Medicine News:Health News:Treatment Advances Improve the Odds for Heart Failure Patients 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 3Health News:Cell signaling discovery provides new hope for blood disorders 2Health News:High doses of 'load' slows loss of bone in spinal cord injury 2Health News:High doses of 'load' slows loss of bone in spinal cord injury 3Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 2Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 3Health News:Arsenic Might Be Found in Some Organic Foods: Study 2Health News:Arsenic Might Be Found in Some Organic Foods: Study 3Health News:painACTION.com improves migraine self-management and reduces migraine-related psychological distress 2
Hardee bone rongeur made with the highest quality to meet the exacting standards expected in your surgical specialty....
Hibbs Retractor with sharp teeth. Used for deep soft tissue retraction....
Traditional design utility pliers have adjustable jaws. Good all purpose plier for handling Steinmann Pins, K-Wires, screws and rods. 10mm jaw tip....
Heavy Duty Locking Pliers...
Medicine Products: